Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.
Mercuri, Eugenio; Deconinck, Nicolas; Mazzone, Elena S.et al.
[en] BACKGROUND: Risdiplam is an oral small molecule approved for the treatment of patients with spinal muscular atrophy, with approval for use in patients with type 2 and type 3 spinal muscular atrophy granted on the basis of unpublished data. The drug modifies pre-mRNA splicing of the SMN2 gene to increase production of functional SMN. We aimed to investigate the safety and efficacy of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy. METHODS: In this phase 3, randomised, double-blind, placebo-controlled study, patients aged 2-25 years with confirmed 5q autosomal recessive type 2 or type 3 spinal muscular atrophy were recruited from 42 hospitals in 14 countries across Europe, North America, South America, and Asia. Participants were eligible if they were non-ambulant, could sit independently, and had a score of at least 2 in entry item A of the Revised Upper Limb Module. Patients were stratified by age and randomly assigned (2:1) to receive either daily oral risdiplam, at a dose of 5·00 mg (for individuals weighing ≥20 kg) or 0·25 mg/kg (for individuals weighing <20 kg), or daily oral placebo (matched to risdiplam in colour and taste). Randomisation was conducted by permutated block randomisation with a computerised system run by an external party. Patients, investigators, and all individuals in direct contact with patients were masked to treatment assignment. The primary endpoint was the change from baseline in the 32-item Motor Function Measure total score at month 12. All individuals who were randomly assigned to risdiplam or placebo, and who did not meet the prespecified missing item criteria for exclusion, were included in the primary efficacy analysis. Individuals who received at least one dose of risdiplam or placebo were included in the safety analysis. SUNFISH is registered with ClinicalTrials.gov, NCT02908685. Recruitment is closed; the study is ongoing. FINDINGS: Between Oct 9, 2017, and Sept 4, 2018, 180 patients were randomly assigned to receive risdiplam (n=120) or placebo (n=60). For analysis of the primary endpoint, 115 patients from the risdiplam group and 59 patients from the placebo group were included. At month 12, the least squares mean change from baseline in 32-item Motor Function Measure was 1·36 (95% CI 0·61 to 2·11) in the risdiplam group and -0·19 (-1·22 to 0·84) in the placebo group, with a treatment difference of 1·55 (0·30 to 2·81, p=0·016) in favour of risdiplam. 120 patients who received risdiplam and 60 who received placebo were included in safety analyses. Adverse events that were reported in at least 5% more patients who received risdiplam than those who received placebo were pyrexia (25 [21%] of 120 patients who received risdiplam vs ten [17%] of 60 patients who received placebo), diarrhoea (20 [17%] vs five [8%]), rash (20 [17%] vs one [2%]), mouth and aphthous ulcers (eight [7%] vs 0), urinary tract infection (eight [7%] vs 0), and arthralgias (six [5%] vs 0). The incidence of serious adverse events was similar between treatment groups (24 [20%] of 120 patients in the risdiplam group; 11 [18%] of 60 patients in the placebo group), with the exception of pneumonia (nine [8%] in the risdiplam group; one [2%] in the placebo group). INTERPRETATION: Risdiplam resulted in a significant improvement in motor function compared with placebo in patients aged 2-25 years with type 2 or non-ambulant type 3 spinal muscular atrophy. Our exploratory subgroup analyses showed that motor function was generally improved in younger individuals and stabilised in older individuals, which requires confirmation in further studies. SUNFISH part 2 is ongoing and will provide additional evidence regarding the long-term safety and efficacy of risdiplam. FUNDING: F Hoffmann-La Roche.
Disciplines :
Pediatrics Neurology
Author, co-author :
Mercuri, Eugenio
Deconinck, Nicolas
Mazzone, Elena S.
Nascimento, Andres
Oskoui, Maryam
Saito, Kayoko
Vuillerot, Carole
Baranello, Giovanni
Boespflug-Tanguy, Odile
Goemans, Nathalie
Kirschner, Janbernd
Kostera-Pruszczyk, Anna
Servais, Laurent ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Gerber, Marianne
Gorni, Ksenija
Khwaja, Omar
Kletzl, Heidemarie
Scalco, Renata S.
Staunton, Hannah
Yeung, Wai Yin
Martin, Carmen
Fontoura, Paulo
Day, John W.
Daron, Aurore ; Université de Liège - ULiège > Département des sciences cliniques ; SUNFISH Study Group
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.
Lefebvre, S, Bürglen, L, Reboullet, S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80 (1995), 155–165.
Talbot, K, Tizzano, EF, The clinical landscape for SMA in a new therapeutic era. Gene Ther 24 (2017), 529–533.
Lorson, CL, Hahnen, E, Androphy, EJ, Wirth, B, A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 96 (1999), 6307–6311.
Singh, RN, Howell, MD, Ottesen, EW, Singh, NN, Diverse role of survival motor neuron protein. Biochim Biophys Acta Gene Regul Mech 1860 (2017), 299–315.
Kaufmann, P, McDermott, MP, Darras, BT, et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol 68 (2011), 779–786.
Biogen. SPINRAZA (nusinersen) for intrathecal use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf, December, 2016. (Accessed 11 November 2021)
Biogen. Summary of product characteristics. https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004312/WC500229704.pdf, December, 2017. (Accessed 11 November 2021)
US Food and Drug Administration. ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion. https://www.fda.gov/media/126109/download, May, 2019. (Accessed 11 November 2021)
European Medicines Agency. Zolgensma. https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma, May, 2020. (Accessed 11 November 2021)
Ratni, H, Ebeling, M, Baird, J, et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem 61 (2018), 6501–6517.
US Food and Drug Administration. EVRYSDI (risdiplam) for oral solution. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213535s000lbl.pdf, Aug, 2020. (Accessed 11 November 2021)
European Medicines Agency. Summary of opinion (initial authorisation). https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-evrysdi_en.pdf, Feb 25, 2021. (Accessed 11 November 2021)
Day, J, Baranello, G, Boespflug-Tanguy, O, et al. P.263 SUNFISH Part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) treatment in patients with Type 2 or 3 spinal muscular atrophy (SMA). Neuromuscul Disord, 30, 2020, S123.
Bérard, C, Payan, C, Hodgkinson, I, Fermanian, J, A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord 15 (2005), 463–470.
Mazzone, E, Revised Upper Limb Module for SMA (RULM FOR SMA). https://columbiasma.org/docs/cme-2010/RULM-Generic-Manual-16-Dec-2014.pdf, Dec 16, 2014. (Accessed 11 November 2021)
Immohr, LI, Dischinger, A, Kühl, P, Early pediatric formulation development with new chemical entities: opportunities of e-tongue besides human taste assessment. Int J Pharm 530 (2017), 201–212.
Sturm, S, Günther, A, Jaber, B, et al. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol 85 (2019), 181–193.
Trundell, D, Le Scouiller, S, Gorni, K, Seabrook, T, Vuillerot, C, Validity and reliability of the 32-Item Motor Function Measure in 2- to 5-Year-olds with neuromuscular disorders and 2- to 25-year-olds with spinal muscular atrophy. Neurol Ther 9 (2020), 575–584.
Trundell, D, Le Scouiller, S, Le Goff, L, Gorni, K, Vuillerot, C, Assessment of the validity and reliability of the 32-item Motor Function Measure in individuals with type 2 or non-ambulant type 3 spinal muscular atrophy. PLoS One, 15, 2020, e0238786.
US Food and Drug Administration. Patient-focused drug developmeny guidance public workshop: methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. https://www.fda.gov/media/116277/download, Sept 17, 2018. (Accessed 11 November 2021)
Coon, CD, Cook, KF, Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores. Qual Life Res 27 (2018), 33–40.
Cruz, R, Lenz, M, Belter, L, Hobby, K, Jarecki, J, Smart, T, CureSMA: voice of the patient report. https://www.curesma.org/wp-content/uploads/2018/01/SMA-VoP-for-publication-1-22-2018.pdf, Jan 10, 2018. (Accessed 11 November 2021)
Gusset, N, Stalens, C, Stumpe, E, et al. Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy. Neuromuscul Disord 31 (2021), 419–430.
Vuillerot, C, Payan, C, Iwaz, J, Ecochard, R, Bérard, C, Responsiveness of the motor function measure in patients with spinal muscular atrophy. Arch Phys Med Rehabil 94 (2013), 1555–1561.
Annoussamy, M, Seferian, AM, Daron, A, et al. Natural history of type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann Clin Transl Neurol 8 (2021), 359–373.
Mercuri, E, Finkel, R, Montes, J, et al. Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials. Neuromuscul Disord 26 (2016), 126–131.
Wijngaarde, CA, Veldhoen, ES, van Eijk, RPA, et al. Natural history of lung function in spinal muscular atrophy. Orphanet J Rare Dis, 15, 2020, 88.
Trucco, F, Ridout, D, Scoto, M, et al. Respiratory trajectories in type 2 and 3 spinal muscular atrophy in the iSMAC cohort study. Neurology 96 (2021), e587–e599.
Mercuri, E, Darras, BT, Chiriboga, CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378 (2018), 625–635.
Mercuri, E, Lucibello, S, Pera, MC, et al. Long-term progression in type II spinal muscular atrophy: a retrospective observational study. Neurology 93 (2019), e1241–e1247.
Wijngaarde, CA, Stam, M, Otto, LAM, et al. Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Neurology 95 (2020), e1988–e1998.
Trundell D, Skalicky A, Staunton H, et al. Development of the SMA Independence Scale-Upper Limb Module: a novel scale for individuals with type 2 and non-ambulant type 3 SMA. J Neurol Sci (in press).